Search

Your search keyword '"Kostas Vekrellis"' showing total 73 results

Search Constraints

Start Over You searched for: Author "Kostas Vekrellis" Remove constraint Author: "Kostas Vekrellis"
73 results on '"Kostas Vekrellis"'

Search Results

1. α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes

2. SIMOA Diagnostics on Alzheimer’s Disease and Frontotemporal Dementia

3. Recommendations for reproducibility of cerebrospinal fluid extracellular vesicle studies

4. Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption

5. The promise of the TGF-β superfamily as a therapeutic target for Parkinson's disease

6. Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease

7. Assessment of Aggregated and Exosome-Associated α-Synuclein in Brain Tissue and Cerebrospinal Fluid Using Specific Immunoassays

8. A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration

9. A chemogenomic approach is required for effective treatment of amyotrophic lateral sclerosis

10. Intrastriatal Administration of Exosome-Associated Pathological Alpha-Synuclein Is Not Sufficient by Itself to Cause Pathology Transmission

11. Voltage-Gated Calcium Channels and α-Synuclein: Implications in Parkinson’s Disease

12. ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons

13. The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease.

14. Assessment of α-synuclein secretion in mouse and human brain parenchyma.

15. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy.

16. Assessment of Aggregated and Exosome-Associated α-Synuclein in Brain Tissue and Cerebrospinal Fluid Using Specific Immunoassays

17. Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers

18. Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption

19. Changes in the cellular fatty acid profile drive the proteasomal degradation of α‐synuclein and enhance neuronal survival

20. Quantitative determination of aloin, antioxidant activity, and toxicity of <scp> Aloe vera </scp> leaf gel products from Greece

21. Investigating the presence of doubly phosphorylated α‐synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases

22. Peripheral alpha-synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease

23. Elevated Serum α-Synuclein Levels in Huntington’s Disease Patients

24. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity

25. A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration

26. A chemogenomic approach seems indispensable for effective treatment of amyotrophic lateral sclerosis

27. Assessment of cerebrospinal fluid α-synuclein as a potential biomarker in Parkinson’s disease and synucleinopathies

28. Heterogeneity in α‐synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease

29. An integrated bacterial system for the discovery of chemical rescuers of disease-associated protein misfolding

30. Nuclear Receptor NR5A2 Promotes Neuronal Identity in the Adult Hippocampus

31. Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype

32. Voltage-Gated Calcium Channels and α-Synuclein: Implications in Parkinson’s Disease

33. Cellular models of alpha-synuclein toxicity and aggregation

35. Exocytosis and Spreading of Normal and Aberrant α-Synuclein

36. 'Activography': a novel, versatile and easily adaptable method for monitoring enzymatic activities in situ

37. Screening for Novel Inhibitors of Beta Amyloid Aggregation and Toxicity as a Potential Drug for Alzheimer's Disease

38. Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease

39. The role of the endoplasmic reticulum stress response following cerebral ischemia

40. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes

41. Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice

42. Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like Propagation

43. The small GTPase Rab11 co-localizes with -synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity

44. Tsc1 (hamartin) confers neuroprotection against ischemia by inducing autophagy

45. Cell-produced α-synuclein oligomers are targeted to, and impair, the 26S proteasome

46. Wild Type α-Synuclein Is Degraded by Chaperone-mediated Autophagy and Macroautophagy in Neuronal Cells

47. GABA transmission via ATP-dependent K+ channels regulates α-synuclein secretion in mouse striatum

48. RAIDD aggregation facilitates apoptotic death of PC12 cells and sympathetic neurons

49. Neurobiology of α-Synuclein

50. Publisher Correction: An integrated bacterial system for the discovery of chemical rescuers of disease-associated protein misfolding

Catalog

Books, media, physical & digital resources